Karl Schultheiss, MD
Medical Oncology · Bend, ORNPI 1265478325
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.6% of the total across 89 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 9.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $660 and has fallen 74.9% since, to $166 in 2025.
Across 89 payments — averaging $21.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$169
- Merck$159
- AstraZeneca$156
- Pfizer$127
- Seagen Inc.$117
- Janssen Scientific Affairs, LLC$107
- plus $1K from 27 others
Across 34 payments — averaging $6047.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$68K
- Amgen$40K
- Genentech, Inc.$30K
- E.r. Squibb & Sons, L.L.C.$22K
- Merck$17K
- Incyte Corporation$16K
- plus $13K from 4 others
What the payments were for
- Food & beverage$1,75394%
- Education$1206%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 9 | $169 |
| Merck | 8 | $159 |
| AstraZeneca | 7 | $156 |
| Pfizer | 7 | $127 |
| Seagen Inc. | 2 | $117 |
| Janssen Scientific Affairs, LLC | 1 | $107 |
| Novartis | 5 | $105 |
| Bristol Myers Squibb | 4 | $102 |
| Genentech USA, Inc. | 5 | $101 |
| Johnson & Johnson | 3 | $74 |
| GSK | 3 | $70 |
| Daiichi Sankyo Inc. | 3 | $70 |
| EMD Serono, Inc. | 4 | $60 |
| AbbVie | 3 | $51 |
| Regeneron Healthcare Solutions, Inc. | 2 | $41 |
| Acrotech Biopharma Inc. | 2 | $41 |
| Sanofi | 2 | $33 |
| Incyte Corporation | 2 | $33 |
| Lilly USA, LLC | 2 | $30 |
| Gilead | 2 | $25 |
| Array Biopharma Inc | 1 | $21 |
| Karyopharm Therapeutics Inc. | 1 | $19 |
| Mirati Therapeutics, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $17 |
| Tersera Therapeutics LLC | 1 | $16 |
| Beone Medicines USA, Inc. | 1 | $16 |
| AVEO Pharmaceuticals, Inc. | 1 | $15 |
| Sobi, Inc | 1 | $15 |
| Myovant Sciences Inc. | 1 | $14 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Beigene USA, Inc. | 1 | $12 |
| Clovis Oncology, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,874 in reported general payments places this provider in the 60th percentile of 92 medical oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 20 | $333,949 |
| VonjoPacritinib Citrate | 14 | $309,803 |
| PomalystPomalidomide | 12 | $272,992 |
| CalquenceAcalabrutinib Maleate | 17 | $257,848 |
| RevlimidLenalidomide | 11 | $150,074 |
| EliquisApixaban | 48 | $34,725 |
| Abiraterone Acetate | 19 | $27,408 |
| XareltoRivaroxaban | 11 | $11,609 |
| Enoxaparin Sodium | 13 | $7,054 |
| Letrozole | 92 | $2,370 |
| Dapsone | 13 | $1,641 |
| Tamoxifen Citrate | 34 | $1,117 |
| Prochlorperazine Maleate | 49 | $1,003 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 42 | $887 |
| Acyclovir | 52 | $747 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso, Calquence | $156 | $591,79737 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $169 | $272,99212 claims |
| Bristol Myers SquibbRevlimid | $102 | $150,07411 claims |
| PfizerEliquis | $127 | $34,72548 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $107 | $27,40819 claims |
| Johnson & JohnsonXarelto | $74 | $11,60911 claims |
| Lilly USA, LLCOlanzapine | $30 | $17212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 92 medical oncology providers in Oregon.
Other medical oncology in Bend
- Hyung Chil KangBend$7K
- Stephen KornfeldBend$3K
- Theodore BraichBend$343
- William MartinBend$317
- Jeff SharmanEugene$264K
- David PagePortland$238K
- Rachel SanbornPortland$233K
- Matthew TaylorPortland$231K
- Tomasz BeerPortland$102K
- Alison ConlinPortland$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.